A new report looks at cancer drug development strategies in colorectal cancer, lung cancer and the compound strategy of antibodies to compare drug development strategies in oncology, according to a Research and Markets news release.
The report analyzes development strategies for 347 colorectal cancer drugs in different stages of development. The analysis looks at drug targets and drug target strategies.
Related Articles on Drug Development:
MIT Researcher: Device and Drug Combos Carry Greater Risk, Reward
USC School of Pharmacy Establishes International Center for Regulatory Science
FDA Reports Increase in New Drug Approvals in FY 2011
The report analyzes development strategies for 347 colorectal cancer drugs in different stages of development. The analysis looks at drug targets and drug target strategies.
Related Articles on Drug Development:
MIT Researcher: Device and Drug Combos Carry Greater Risk, Reward
USC School of Pharmacy Establishes International Center for Regulatory Science
FDA Reports Increase in New Drug Approvals in FY 2011